A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer

LESSONS LEARNED. Ideally, patients should have access to an oral formulation of paclitaxel, as well as an intravenous formulation, to allow development of regimens exploring alternate schedules and to avoid reactions to Cremophor EL (BASF Corp., Ludwigshafen, Germany, https://www.basf.com). DHP107 i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Ryu, Min‐Hee, Ryoo, Baek‐Yeol, Kim, Tae Won, Kim, Sung Bae, Lim, Hyeong‐Seok, Bae, Kyun‐Seop, Park, Sook Ryun, Jo, Yeong‐Woo, Cho, Hyun Ju, Kang, Yoon‐Koo
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2017
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5330712/
https://ncbi.nlm.nih.gov/pubmed/28196905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0273
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky